Key Documents

View All Documentation

P2116

Pirfenidone

Name: Pirfenidone
Brand: SIGMA

≥97% (HPLC), powder, antifibrotic agent

Synonym(s):

5-Methyl-1-phenyl-2-(1H)-pyridone

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₂H₁₁NO

CAS Number:

53179-13-8

Molecular Weight:

185.22

UNSPSC Code:

12352200

PubChem Substance ID:

24278625

NACRES:

NA.77

MDL number:

MFCD00866047

Assay:

≥97% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Pirfenidone, ≥97% (HPLC)

Quality Level

100

assay

≥97% (HPLC)

form

powder

solubility

H₂O: >10 mg/mL at 60 °C (warming for 30 minutes), DMSO: >20 mg/mL

originator

Shionogi

SMILES string

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChI key

ISWRGOKTTBVCFA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

General description

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.

Application

Pirfenidone has been used:

as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia

Biochem/physiol Actions

Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival. Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.

Inhibits collagen production and fibroblast proliferation.

Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.

Features and Benefits

This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro

Stahnke T, et al.

Testing, 12(2), e0172592-e0172592 (2017)

Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.

Peyman Bizargity et al.

Transplantation, 94(2), 114-122 (2012-06-30)

Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on

Pirfenidone: in idiopathic pulmonary fibrosis.

Natalie J Carter

Drugs, 71(13), 1721-1732 (2011-09-10)

Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Arata Azuma

Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)

Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the

Current and novel drug therapies for idiopathic pulmonary fibrosis.

Huzaifa I Adamali et al.

Drug design, development and therapy, 6, 261-272 (2012-10-12)

Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the

View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Global Trade Item Number

SKU	GTIN
P2116-10MG	04061834362500
P2116-50MG	04061834362517

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service